The U.S. Food and Drug Administration approved Astellas' therapy to treat a type of gastric cancer, the health regulator's ...

Recent clinical research from BGI Genomics and Zhongshan Hospital, Fudan University, highlights the effectiveness of ...

FDA also approved the Ventana CLDN18 (43-14A) RxDx Assay, from Ventana Medical Systems, Inc. and Roche Diagnostics, to ...

is a risk factor for esophageal cancer. Barrett's esophagus is caused by gastroesophageal reflux disease (GERD), which occurs when stomach acid repeatedly flows back into the esophagus ...

A ChatGPT-like model can diagnose cancer, assist in selecting treatment options, and predict survival outcomes across various ...

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food and Drug Administration (FDA) has approved VYLOY™ (zolbetuximab-clzb) in combination ...

Cancer of the esophagus — the muscular tube that moves food from the mouth into the stomach — has just a 20% five-year ...

In stomach cancer, the three drug developers ... M.D., from Harvard Medical School. As for the esophageal cancer discussion, the ODAC members spent some time on how difficult it was to interpret ...

Jeff Pinski, 79, was at higher risk of throat cancer due to Barrett's esophagus. He previously battled skin, bladder and ...

VYLOY is the first and only CLDN18.2-targeted treatment approved in the U.S. for adults with advanced gastric and gastroesophageal junction cancer whose tumors are CLDN18.2 positive TOKYO, Oct. 18 ...

The FDA had also approved nivolumab in combination with ipilimumab for esophageal cancer, regardless of PD ... microsatellite-stable gastric/gastroesophageal adenocarcinoma approval trials across ...